Concord Wealth Partners’s Yield10 Bioscience, Inc. Common Stock YTEN Stock Holding History

Concord Wealth Partners’s Portfolio YTEN Stock Details YTEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-146	Closed	-$7.77K	–	1083
2023 Q2	$7.77K	Hold	146	–	–	﹤0.01%	643
2023 Q1	$9.66K	Hold	146	–	–	﹤0.01%	597
2022 Q4	$5.84K	Buy	+146	New	+$8.69K	﹤0.01%	727
2022 Q3	–	Sell	-146	Closed	-$8K	–	1240
2022 Q2	$8K	Hold	146	–	–	﹤0.01%	742
2022 Q1	$19K	Buy	+146	New	+$15.1K	﹤0.01%	646

Other funds holding YTEN

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Concord Wealth Partners's YTEN Position: Q3 2023 in Review

Concord Wealth Partners sold out of Yield10 Bioscience, Inc. Common Stock (YTEN) in Q3 2023, closing a stake of 146 shares — an estimated $7.77K sold.

Concord Wealth Partners first reported a position in YTEN in Q1 2022 and held it in 5 quarters. The position peaked at $19K in Q1 2022. 15 funds tracked by Wall St. Rank hold YTEN as of Q3 2023.

Concord Wealth Partners reported no remaining Yield10 Bioscience, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Concord Wealth Partners sold 146 Yield10 Bioscience, Inc. Common Stock shares in Q3 2023, an estimated $7.77K.
Concord Wealth Partners first reported a position in Yield10 Bioscience, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Concord Wealth Partners's Yield10 Bioscience, Inc. Common Stock position peaked at $19K in Q1 2022.
15 funds tracked by Wall St. Rank held Yield10 Bioscience, Inc. Common Stock as of Q3 2023.

Based on Concord Wealth Partners's 13F filing for Q3 2023, filed 25 Oct 2023.